Användning av cookies

Lunds universitet använder cookies för att se till att webbplatsen fungerar korrekt och för att förbättra din upplevelse.

Läs mer i vår cookiepolicy

Sökresultat

Filtrera

Nollställ filter

Filtyp

Din sökning på "*" gav 534600 sökträffar

Joint channel estimation and peak-to-average power reduction in coherent OFDM: a novel approach

A new peak-to-average power reduction approach for OFDM has been addressed. Two-dimensional pilot-symbol assisted modulation (2D-PSAM) is employed in coherent OFDM for channel estimation and it is based on inserting known symbols spreaded out throughout the 2D time-frequency grid. We show that these scattered symbols can also be employed to perform distortionless peak power reduction, with a negli

A 2.4 GHz CMOS power amplifier using internal frequency doubling

A fully integrated 0.18 μm 1P6M CMOS power amplifier using internal frequency doubling is presented. Two chips were measured, one stand-alone PA and one PA with a VCO on the same chip. Since the PA and VCO operate at different frequencies, this configuration is suitable for direct-upconversion or low-IF upconversion since oscillator pulling is reduced. The maximum output power is 15 dBm, and the m

Metabolic engineering and random mutagenesis for improved xylose utilisation of Saccharomyces cerevisiae

In this thesis I have summarised my work on the analysis and improvement of xylose utilisation by recombinant S. cerevisiae. A metabolic flux model was developed and used to analyse the intracellular fluxes in the recombinant xylose utilising S. cerevisiae TMB 3001 cultivated in chemostat at various dilution rates and xylose/glucose concentrations. Xylose uptake increased with xylose concentration

Quantification Methods for Clinical Studies in Nuclear Medicine - Applications in AMS, PET/CT and SPECT/CT

Popular Abstract in Swedish Inom området diagnostisk nuklearmedicin används radioaktiva läkemedel som ges (administreras) till patienterna i syfte att diagnostisera ett antal olika sjukdomstillstånd. Då man tar fram nya radioaktiva läkemedel för användning inom diagnostisk nuklearmedicin handlar det många gånger om att uppskatta mängden av ett visst upptag av radiofarmakat i olika organ och vävnadAn essential part of the development of new radiopharmaceuticals for use in diagnostic nuclear medicine is the determination of its biokinetic properties. The uptake and turn-over of the radiopharmaceutical in the source organs is of great interest since this could determine whether the radiopharmaceutical would be suitable for clinical use or not. It is also important that the biokinetics and dos